GeneHealth - Your precision medicine

Dilated Cardiomyopathy 1k

Disease Details

Family Health Simplified

Buy Membership

Description: Dilated cardiomyopathy 1K is a genetic disorder characterized by the enlargement and weakening of the heart's ventricles, leading to impaired cardiac function and heart failure.
Type: Dilated cardiomyopathy 1K (DCM1K) is primarily a type of genetic disease known as a cardiomyopathy, specifically affecting the heart muscle's ability to contract efficiently. The type of genetic transmission for DCM1K is autosomal recessive. This means two copies of the defective gene, one inherited from each parent, are required for an individual to express the disease.
Signs And Symptoms: **Dilated Cardiomyopathy (DCM) - Signs and Symptoms:**
1. Shortness of breath, especially with exertion or lying flat
2. Fatigue
3. Swelling in the legs, ankles, and feet (edema)
4. Weight gain due to fluid retention
5. Persistent cough or wheezing, especially when lying down
6. Irregular or rapid heartbeat (arrhythmias)
7. Dizziness, lightheadedness, or fainting
8. Reduced ability to exercise
9. Chest pain or discomfort

**DCM is typically characterized by an enlarged and weakened left ventricle, which impairs the heart's ability to pump blood effectively. Symptoms often arise due to the heart's reduced capacity to meet the body's needs.**
Prognosis: Dilated cardiomyopathy 1K (DCM1K) prognosis can vary significantly depending on factors such as the severity of the disease, the patient's overall health, response to treatment, and the presence of any complications such as heart failure or arrhythmias. Prognosis is often worse in cases where the disease is diagnosed at a more advanced stage. Advanced medical therapies, lifestyle changes, and in some cases, surgical interventions can help manage the condition and improve quality of life. Regular follow-ups with a healthcare provider are essential to monitor and manage the disease effectively.
Onset: The "nan" entry in your query seems to be unclear, but I can provide information on the onset of dilated cardiomyopathy (DCM).

Dilated cardiomyopathy (DCM) can occur at any age, but it is most commonly diagnosed in middle-aged individuals, particularly between 20 and 60 years old. It can be idiopathic, familial, or due to other factors such as infections, toxins, or metabolic conditions. The presentation can vary from being asymptomatic to severe heart failure symptoms.
Prevalence: The prevalence of dilated cardiomyopathy (DCM) caused by mutations in the gene LMNA (often referred to as dilated cardiomyopathy 1K) is not well-defined due to its rarity and the variability in diagnosis. However, LMNA mutations are estimated to account for about 5-10% of familial DCM cases.
Epidemiology: Dilated cardiomyopathy 1K (DCM1K) is a genetic form of dilated cardiomyopathy caused by mutations in the LMNA gene, which encodes lamin A/C proteins. These proteins are crucial for maintaining the structural integrity of the cell nucleus in cardiac muscle cells. The epidemiological data specific to DCM1K are limited, but dilated cardiomyopathy as a whole has a prevalence of approximately 1 in 250 individuals globally. Genetic forms of DCM account for up to 40% of all cases of dilated cardiomyopathy, according to various studies.
Intractability: Dilated cardiomyopathy (DCM) can be challenging to manage, but it is not necessarily intractable. Treatment options are available and can help improve symptoms and quality of life. Management typically includes medications, lifestyle changes, and sometimes devices like pacemakers or defibrillators. In severe cases, a heart transplant may be considered. The effectiveness of treatments can vary depending on the individual's specific condition and underlying causes.
Disease Severity: Dilated Cardiomyopathy 1K, a subtype of dilated cardiomyopathy that is often a genetic disorder, can vary significantly in severity. Disease severity ranges from asymptomatic cases to severe heart failure. Severity is influenced by a variety of factors, including the specific genetic mutation, environmental factors, and individual health conditions. Regular monitoring and medical management are crucial to manage and mitigate symptoms.
Healthcare Professionals: Disease Ontology ID - DOID:0110437
Pathophysiology: Dilated cardiomyopathy 1K (DCM1K) is primarily characterized by the dilation and impaired contraction of the left ventricle, which is the heart's main pumping chamber. This leads to a decreased ability of the heart to pump blood efficiently, causing heart failure and arrhythmias. The condition is often inherited in an autosomal dominant pattern and is linked to mutations in the TTN gene, among others, which encodes for the protein titin. Titin is crucial for maintaining the structural integrity and elasticity of heart muscle cells. Mutations in this gene lead to defective titin, contributing to myocardial dysfunction and ventricular dilation.
Carrier Status: The available information on "dilated cardiomyopathy 1K" does not include specific details regarding genetic testing for carrier status. Further genetic consultation and testing are recommended for precise carrier status determination.
Mechanism: Dilated cardiomyopathy 1K (DCM1K) is a form of dilated cardiomyopathy, which is characterized by the enlargement and weakening of the heart's left ventricle. It is generally inherited in an autosomal dominant manner.

**Mechanism:**
The primary mechanism involves the progressive dilation of the left ventricle, which compromises the heart's ability to pump blood efficiently. Over time, this leads to congestive heart failure and associated symptoms such as shortness of breath, fatigue, and fluid retention.

**Molecular Mechanisms:**
DCM1K often involves mutations in the LMNA gene, which encodes lamins A and C—proteins that are key structural components of the nuclear envelope. Mutations in the LMNA gene can disrupt the structural integrity of the nuclear envelope and impair cellular functions, including gene transcription and cell cycle regulation, ultimately leading to myocardial cell damage and weakening.

Further molecular mechanisms may include:
1. **Cytoskeletal Disruption:** Mutations affect the stability of the cytoskeleton, leading to impaired force transmission and cellular contractility.
2. **Impaired Signal Transduction:** Altered signaling pathways that are essential for cell survival and function.
3. **Oxidative Stress:** Increased stress on heart muscle cells can exacerbate cellular damage and contribute to disease progression.
4. **Apoptosis and Fibrosis:** Enhanced cell death and abnormal repair processes result in fibrotic tissue, which further weakens cardiac function.

Understanding these molecular mechanisms is crucial for developing targeted therapies and managing the disease effectively.
Treatment: Treatment for dilated cardiomyopathy (DCM) generally involves managing symptoms, improving heart function, and preventing complications. Common treatments include:

1. **Medications**:
- **ACE Inhibitors**: To relax blood vessels, lower blood pressure, and improve blood flow.
- **Beta-blockers**: To slow the heart rate and reduce the workload on the heart.
- **Diuretics**: To reduce fluid buildup in the body.
- **Aldosterone antagonists**: To decrease salt and water retention.

2. **Lifestyle Changes**:
- Diet modifications (low-sodium diet).
- Regular exercise as advised by a healthcare provider.
- Avoiding alcohol and smoking.

3. **Devices**:
- **Implantable Cardioverter-Defibrillators (ICDs)**: To correct life-threatening arrhythmias.
- **Pacemakers**: To help control abnormal heart rhythms.

4. **Surgery**:
- **Heart Transplant**: In severe cases where other treatments are ineffective.
- **Left Ventricular Assist Devices (LVADs)**: Mechanical pumps that help the heart pump blood.

5. **Regular Monitoring**: Frequent check-ups with a cardiologist to monitor heart function and adjust treatment as needed.

Nan (not a number) is not applicable in the context of this treatment discussion.
Compassionate Use Treatment: For dilated cardiomyopathy (DCM) with the specific genetic subtype 1k (DCM1K), compassionate use treatment and off-label or experimental treatments might be considered in certain cases. Compassionate use treatment refers to the use of investigational drugs or therapies outside of clinical trials for patients with serious or life-threatening conditions when no comparable or satisfactory therapy options are available. Here are some potential approaches:

1. **Gene Therapy**: As DCM1K is a genetic condition, experimental gene therapy aimed at correcting the underlying genetic defect may be pursued. This approach is still largely in the research and clinical trial phases.

2. **Myosin Modulators**: Drugs that modulate heart muscle contraction, such as omecamtiv mecarbil, are being explored in clinical trials. These drugs are considered investigational but could be accessed via compassionate use.

3. **Stem Cell Therapy**: Experimental treatments involving the use of stem cells to repair damaged heart tissue are being studied. These are not yet widely available outside of clinical trials but can be considered for compassionate use.

4. **Electrical Device Therapy**: Off-label use of devices such as left ventricular assist devices (LVADs) or cardiac resynchronization therapy (CRT) may be considered in severe cases to improve heart function.

5. **Pharmacological Interventions**: Off-label use of certain medications that are typically used for heart failure management, such as angiotensin receptor-neprilysin inhibitors (ARNIs) or SGLT2 inhibitors, might be considered even if they don't specifically address the genetic aspect of DCM1K.

It is essential for patients and caregivers to consult with a cardiologist or a specialist in genetic heart disorders to evaluate the suitability and availability of these compassionate or experimental treatments.
Lifestyle Recommendations: Dilated cardiomyopathy (DCM) is a condition characterized by the enlargement and weakening of the heart's left ventricle, leading to decreased heart function. For managing DCM, lifestyle recommendations include:

1. **Diet**: Follow a heart-healthy diet that is low in salt, saturated fats, and cholesterol. Emphasize fruits, vegetables, whole grains, lean proteins, and healthy fats like those found in fish and nuts.

2. **Exercise**: Engage in regular, moderate aerobic exercise as tolerated and recommended by a healthcare provider. Avoid intense or competitive sports.

3. **Weight Management**: Maintain a healthy weight to reduce cardiac stress.

4. **Alcohol and Substance Use**: Limit or avoid alcohol intake. Do not use recreational drugs.

5. **Medications**: Adhere strictly to prescribed medications to manage symptoms and prevent complications.

6. **Stress Management**: Practice stress-reducing techniques such as mindfulness, meditation, or yoga.

7. **Routine Monitoring**: Keep regular appointments with a healthcare provider for monitoring the condition.

8. **Smoking**: Quit smoking and avoid exposure to secondhand smoke.

9. **Vaccinations**: Stay up-to-date on vaccinations, including the flu and pneumonia vaccines, to prevent infections that could strain the heart.

10. **Sleep**: Ensure adequate and quality sleep to support overall health.

11. **Symptom Management**: Be vigilant about symptoms and seek medical advice if there are any significant changes, such as increased shortness of breath, swelling, or fatigue.

These recommendations can help manage dilated cardiomyopathy and improve quality of life. Always consult a healthcare provider for personalized advice and treatment plans.
Medication: For dilated cardiomyopathy (DCM), including various subtypes such as dilated cardiomyopathy 1k, medications commonly prescribed include:

1. **ACE Inhibitors** (e.g., Enalapril, Lisinopril): To reduce blood pressure and decrease the heart's workload.
2. **Beta-Blockers** (e.g., Carvedilol, Metoprolol): To slow the heart rate and reduce blood pressure.
3. **Diuretics** (e.g., Furosemide): To help reduce fluid buildup in the body.
4. **Aldosterone Antagonists** (e.g., Spironolactone): To help manage heart failure symptoms.
5. **Anticoagulants** (e.g., Warfarin): If there's a risk of blood clots.

Specific treatment plans should be tailored to the individual by a healthcare provider.
Repurposable Drugs: Dilated cardiomyopathy 1K is a genetic form of dilated cardiomyopathy, which is the condition where the heart becomes weakened and enlarged and cannot pump blood efficiently. The identification marker "1K" indicates a specific genetic subtype. For the treatment of dilated cardiomyopathy, several drugs are commonly used and may be considered for repurposing, although their effectiveness can vary based on the specific genetic mutation involved. Potential repurposable drugs include:

1. **Beta-blockers** (e.g., carvedilol, metoprolol): These are used to reduce heart rate, lower blood pressure, and prevent further damage to the heart.
2. **ACE inhibitors** (e.g., enalapril, lisinopril): These help relax blood vessels and reduce the workload on the heart.
3. **Angiotensin II receptor blockers (ARBs)** (e.g., losartan, valsartan): Similar to ACE inhibitors, they help relax blood vessels.
4. **Aldosterone antagonists** (e.g., spironolactone, eplerenone): These help remove excess sodium and water from the body, relieving the heart's workload.
5. **Diuretics** (e.g., furosemide, hydrochlorothiazide): These help reduce fluid buildup in the body.
6. **Ivabradine**: Used to reduce the heart rate in patients with chronic heart failure.
7. **Digoxin**: Helps improve heart pumping and control heart rate.

The use of these drugs should be tailored to individual patient needs and may depend on the specific characteristics and progression of the disease. Always consult a healthcare professional before starting any new medication.
Metabolites: Dilated cardiomyopathy 1K (DCM1K) refers to a genetic form of dilated cardiomyopathy caused by mutations in certain genes that affect heart muscle function. It is primarily characterized by the dilation and impaired contraction of the ventricles. While detailed metabolite profiling for this specific genetic variant is limited, general metabolic alterations in dilated cardiomyopathy can include changes in energy metabolism, fatty acid metabolism, and amino acid metabolism. Commonly observed metabolites in dilated cardiomyopathy cases can include elevated levels of lactate, changes in ketone bodies, and alterations in specific amino acids like alanine and branched-chain amino acids.
Nutraceuticals: Dilated cardiomyopathy 1K (DCM1K) is a genetic form of dilated cardiomyopathy caused by mutations in specific genes. Nutraceuticals, which are food-derived products with potential health benefits, may offer supportive care but are not a primary treatment. Common nutraceuticals that may support heart health include omega-3 fatty acids, Coenzyme Q10 (CoQ10), L-carnitine, and taurine. These can potentially improve heart function and reduce symptoms, but they should be used in conjunction with conventional treatments and under the guidance of a healthcare provider.
Peptides: Dilated cardiomyopathy 1K (DCM1K) is a genetic condition that affects the heart muscle, leading to its dilation and impaired contraction. Peptides or proteins involved in this condition often include those that are part of the sarcomere, cytoskeleton, or involved in calcium handling. Key proteins include titin (TTN), which is commonly mutated in dilated cardiomyopathy cases. Specific peptides used for therapeutic or diagnostic purposes would depend on ongoing research and clinical trials, focusing on restoring normal heart function or slowing disease progression.